/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Bristol-Myers Squibb has been lagging behind other drug manufacturers over the past three months, and analysts remain cautious about the stock's prospects.
As Merck outperforms the broader market this year, Wall Street analysts remain optimistic about the stock's prospects.
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.